Delta Asset Management LLC TN Grows Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

Delta Asset Management LLC TN grew its stake in Becton, Dickinson and Company (NYSE:BDX) by 0.8% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 86,100 shares of the medical instruments supplier’s stock after purchasing an additional 663 shares during the period. Becton, Dickinson and Company makes up about 2.3% of Delta Asset Management LLC TN’s portfolio, making the stock its 15th biggest position. Delta Asset Management LLC TN’s holdings in Becton, Dickinson and Company were worth $22,731,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of BDX. McClarren Financial Advisors Inc. boosted its stake in shares of Becton, Dickinson and Company by 4,900.0% during the second quarter. McClarren Financial Advisors Inc. now owns 100 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 98 shares during the period. Glass Jacobson Investment Advisors llc bought a new position in Becton, Dickinson and Company in the second quarter worth approximately $37,000. Altshuler Shaham Ltd purchased a new position in Becton, Dickinson and Company during the 2nd quarter worth $38,000. Tucker Asset Management LLC bought a new stake in shares of Becton, Dickinson and Company in the first quarter valued at about $37,000. Finally, Mcmillion Capital Management Inc. bought a new position in Becton, Dickinson and Company during the 2nd quarter worth about $42,000. 86.72% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. StockNews.com started coverage on shares of Becton, Dickinson and Company in a report on Thursday, October 5th. They issued a “hold” rating for the company. Citigroup dropped their target price on Becton, Dickinson and Company from $282.00 to $260.00 in a research report on Monday, October 2nd. Barclays boosted their price target on Becton, Dickinson and Company from $284.00 to $303.00 and gave the stock an “overweight” rating in a research report on Monday, August 7th. Raymond James dropped their price objective on Becton, Dickinson and Company from $304.00 to $269.00 and set an “outperform” rating on the stock in a research report on Friday, November 10th. Finally, Piper Sandler reduced their target price on shares of Becton, Dickinson and Company from $305.00 to $280.00 and set an “overweight” rating for the company in a report on Friday, November 10th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Becton, Dickinson and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $282.38.

Becton, Dickinson and Company Stock Performance

NYSE BDX traded up $0.14 on Monday, hitting $233.41. 434,913 shares of the company’s stock traded hands, compared to its average volume of 1,178,844. The firm has a market capitalization of $67.71 billion, a PE ratio of 47.03, a P/E/G ratio of 1.88 and a beta of 0.55. Becton, Dickinson and Company has a 1-year low of $225.61 and a 1-year high of $287.32. The firm’s 50-day moving average price is $256.46 and its two-hundred day moving average price is $260.56. The company has a current ratio of 1.31, a quick ratio of 0.81 and a debt-to-equity ratio of 0.57.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, November 9th. The medical instruments supplier reported $3.42 EPS for the quarter, meeting the consensus estimate of $3.42. Becton, Dickinson and Company had a net margin of 7.66% and a return on equity of 13.91%. The company had revenue of $5.09 billion for the quarter, compared to analyst estimates of $5.02 billion. During the same period in the prior year, the company earned $2.75 earnings per share. The firm’s revenue was up 6.8% on a year-over-year basis. As a group, analysts expect that Becton, Dickinson and Company will post 12.84 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, December 29th. Investors of record on Friday, December 8th will be issued a dividend of $0.95 per share. The ex-dividend date of this dividend is Thursday, December 7th. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $0.91. This represents a $3.80 dividend on an annualized basis and a yield of 1.63%. Becton, Dickinson and Company’s dividend payout ratio is 73.39%.

Insider Activity at Becton, Dickinson and Company

In other news, EVP Richard Byrd sold 459 shares of the business’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $274.48, for a total value of $125,986.32. Following the completion of the sale, the executive vice president now directly owns 3,444 shares in the company, valued at $945,309.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Claire Fraser sold 848 shares of the stock in a transaction on Monday, August 28th. The stock was sold at an average price of $281.66, for a total value of $238,847.68. Following the completion of the transaction, the director now directly owns 21,608 shares of the company’s stock, valued at approximately $6,086,109.28. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Richard Byrd sold 459 shares of the firm’s stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $274.48, for a total value of $125,986.32. Following the completion of the transaction, the executive vice president now owns 3,444 shares in the company, valued at approximately $945,309.12. The disclosure for this sale can be found here. 0.31% of the stock is owned by company insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.